1 |
Pichla-Gollon SL, Lin SW, Hensley SE et al (2009) Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 83, 5567-5573
DOI
|
2 |
Calcedo R, Somanathan S, Qin Q et al (2017) Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency. Proc Natl Acad Sci U S A 114, 1655-1659
DOI
|
3 |
Muruve DA, Cotter MJ, Zaiss AK et al (2004) Helperdependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78, 5966-5972
DOI
|
4 |
Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G et al (2015) Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver. Liver Int 35, 1274-1289
DOI
|
5 |
Simek S, Byrnes A, Bauer S (2002) FDA Perspectives on the use of the adenovirus reference material. BioProcess J 1, 40-42
DOI
|
6 |
Fallaux FJ, Bout A, van der Velde I et al (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9, 1909-1917
DOI
|
7 |
Imperiale MJ, Kao HT, Feldman LT, Nevins JR and Strickland S (1984) Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity. Mol Cell Biol 4, 867-874
DOI
|
8 |
Lozier JN, Csako G, Mondoro TH et al (2002) Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 13, 113-124
DOI
|
9 |
Jiang H, Rivera-Molina Y, Gomez-Manzano C et al (2017) Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res 77, 3894-3907
DOI
|
10 |
Swaminathan S and Thimmapaya B (1995) Regulation of adenovirus E2 transcription unit; in the molecular repertoire of adenoviruses III: biology and pathogenesis, Doerfler W and Bohm P (eds.), 177-194, Springer Berlin Heidelberg, Berlin, Heidelberg
|
11 |
Engelhardt JF, Simon RH, Yang Y et al (1993) Adenovirusmediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther 4, 759-769
DOI
|
12 |
Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N and Verma IM (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 92, 1401-1405
DOI
|
13 |
Kaplan JM and Smith AE (1997) Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 8, 1095-1104
DOI
|
14 |
Otake K, Ennist DL, Harrod K and Trapnell BC (1998) Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 9, 2207-2222
DOI
|
15 |
Bett AJ, Prevec L and Graham FL (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67, 5911-5921
DOI
|
16 |
Evans JD and Hearing P (2003) Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation. J Virol 77, 5295-5304
DOI
|
17 |
O'Neal WK, Zhou H, Morral N et al (1998) Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum Gene Ther 9, 1587-1598
DOI
|
18 |
Jozkowicz A, Dulak J, Nanobashvili J, Polterauer P, Prager M and Huk I (2002) Gutless adenoviral vectors - promising tools for gene therapy. European Surgery-Acta Chirurgica Austriaca 34, 95-100
DOI
|
19 |
Croyle MA, Chirmule N, Zhang Y and Wilson JM (2001) "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75, 4792-4801
DOI
|
20 |
Chillon M, Lee JH, Fasbender A and Welsh MJ (1998) Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 5, 995-1002
DOI
|
21 |
Benhar I, London A and Schwartz M (2012) The privileged immunity of immune privileged organs: the case of the eye. Front Immunol 3, 296
DOI
|
22 |
Galea I, Bechmann I and Perry VH (2007) What is immune privilege (not)? Trends Immunol 28, 12-18
DOI
|
23 |
Schiedner G, Hertel S, Johnston M, Biermann V, Dries V and Kochanek S (2002) Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol 76, 1600-1609
DOI
|
24 |
Alemany R, Dai Y, Lou YC et al (1997) Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods 68, 147-159
DOI
|
25 |
Parks RJ and Graham FL (1997) A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 71, 3293-3298
DOI
|
26 |
Parks RJ, Bramson JL, Wan Y, Addison CL and Graham FL (1999) Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol 73, 8027-8034
DOI
|
27 |
Sandig V, Youil R, Bett AJ et al (2000) Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 97, 1002-1007
DOI
|
28 |
Naso MF, Tomkowicz B, Perry WL 3rd and Strohl WR (2017) Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317-334
DOI
|
29 |
Alliegro M, Ferla R, Nusco E, De Leonibus C, Settembre C and Auricchio A (2016) Low-dose gene therapy reduces the frequency of enzyme replacement therapy in a mouse model of lysosomal storage disease. Mol Ther 24, 2054-2063
DOI
|
30 |
Marshall E (1999) Gene therapy death prompts review of adenovirus vector. Science 286, 2244-2245
DOI
|
31 |
Wang D, Tai PWL and Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18, 358-378
DOI
|
32 |
Armbruster N, Lattanzi A, Jeavons M et al (2016) Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Mol Ther Methods Clin Dev 3, 16060
DOI
|
33 |
George LA, Sullivan SK, Giermasz A et al (2017) Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 377, 2215-2227
DOI
|
34 |
Su Q, Sena-Esteves M and Gao G (2019) Purification of the recombinant adenovirus by cesium chloride gradient centrifugation. Cold Spring Harb Protoc 2019, pdb.prot 095547
|
35 |
Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA and Graham FL (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93, 13565-13570
DOI
|
36 |
Palmer D and Ng P (2003) Improved system for helperdependent adenoviral vector production. Mol Ther 8, 846-852
DOI
|
37 |
Jager L, Hausl MA, Rauschhuber C, Wolf NM, Kay MA and Ehrhardt A (2009) A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc 4, 547-564
DOI
|
38 |
Ng P, Beauchamp C, Evelegh C, Parks R and Graham FL (2001) Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 3, 809-815
DOI
|
39 |
Duan D (2018) Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther 26, 2337-2356
DOI
|
40 |
Pierce EA and Bennett J (2015) The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med 5, a017285
DOI
|
41 |
Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 1, 15005
DOI
|
42 |
Cheshenko N, Krougliak N, Eisensmith RC and Krougliak VA (2001) A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Ther 8, 846-854
DOI
|
43 |
Kubo S, Saeki Y, Chiocca EA and Mitani K (2003) An HSV amplicon-based helper system for helper-dependent adenoviral vectors. Biochem Biophys Res Commun 307, 826-830
DOI
|
44 |
Kharraz Y, Guerra J, Pessina P, Serrano AL and MunozCanoves P (2014) Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed Res Int 2014, 965631
DOI
|
45 |
Dudley RW, Lu Y, Gilbert R et al (2004) Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther 15, 145-156
DOI
|
46 |
Gilbert R, Nalbantoglu J, Howell JM et al (2001) Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther 12, 1741-1755
DOI
|
47 |
den Hollander AI, Koenekoop RK, Yzer S et al (2006) Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet 79, 556-561
DOI
|
48 |
Lee W, Xie Y, Zernant J et al (2016) Complex inheritance of ABCA4 disease: four mutations in a family with multiple macular phenotypes. Hum Genet 135, 9-19
DOI
|
49 |
Tsybovsky Y, Molday RS and Palczewski K (2010) The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol 703, 105-125
DOI
|
50 |
Guse K, Sule G, He F et al (2012) 160. Gene therapy for stargardt disease using helper-dependent adenoviral vectors. Mol Ther 20, S64
|
51 |
Harraghy N, Gaussin A and Mermod N (2008) Sustained transgene expression using MAR elements. Curr Gene Ther 8, 353-366
DOI
|
52 |
Lee D, Liu J, Junn HJ, Lee EJ, Jeong KS and Seol DW (2019) No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants. Exp Mol Med 51, 1-18
|
53 |
Wu N, Zhang H, Deng F et al (2014) Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells. Gene Ther 21, 629-637
DOI
|
54 |
Stemmler MP, Hecht A and Kemler R (2005) E-cadherin intron 2 contains cis-regulatory elements essential for gene expression. Development 132, 965-976
DOI
|
55 |
Suzuki M, Cela R, Clarke C, Bertin TK, Mourino S and Lee B (2010) Large-scale production of high-quality helperdependent adenoviral vectors using adherent cells in cell factories. Hum Gene Ther 21, 120-126
DOI
|
56 |
Smaill F, Jeyanathan M, Smieja M et al (2013) A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5, 205ra134
DOI
|
57 |
McElrath MJ, De Rosa SC, Moodie Z et al (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905
DOI
|
58 |
Green CA, Scarselli E, Sande CJ et al (2015) Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med 7, 300ra126
DOI
|
59 |
Harro C, Sun X, Stek JE et al (2009) Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol 16, 1285-1292
DOI
|
60 |
Mennechet FJ, Tran TT, Eichholz K, van de Perre P and Kremer EJ (2015) Ebola virus vaccine: benefit and risks of adenovirus-based vectors. Expert Rev Vaccines 14, 1471-1478
DOI
|
61 |
Scallan CD, Tingley DW, Lindbloom JD, Toomey JS and Tucker SN (2013) An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 20, 85-94
DOI
|
62 |
Alemany R (2014) Oncolytic adenoviruses in cancer treatment. Biomedicines 2, 36-49
DOI
|
63 |
Huang H, Liu Y, Liao W et al (2019) Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat Commun 10, 4801
DOI
|
64 |
Yamamoto M and Curiel DT (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18, 243-250
DOI
|
65 |
Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M and Ng P (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15, 35-46
DOI
|
66 |
Schnell MA, Zhang Y, Tazelaar J et al (2001) Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3, 708-722
DOI
|
67 |
Axelsen TM and Woldbye DPD (2018) Gene therapy for Parkinson's disease, an update. J Parkinsons Dis 8, 195-215
DOI
|
68 |
McGuigan DB, Heon E, Cideciyan AV et al (2017) EYS mutations causing autosomal recessive retinitis pigmentosa: changes of retinal structure and function with disease progression. Genes (Basel) 8, 178
DOI
|
69 |
Pierrache LH, Hartel BP, van Wijk E et al (2016) Visual prognosis in USH2A-associated retinitis pigmentosa is worse for patients with usher syndrome type iia than for those with nonsyndromic retinitis pigmentosa. Ophthalmology 123, 1151-1160
DOI
|
70 |
Sun M, Kong L, Wang X et al (2004) Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum Gene Ther 15, 1177-1196
DOI
|
71 |
Nilsson P, Iwata N, Muramatsu S, Tjernberg LO, Winblad B and Saido TC (2010) Gene therapy in Alzheimer's disease - potential for disease modification. J Cell Mol Med 14, 741-757
DOI
|
72 |
Hammerich L, Marron TU, Upadhyay R et al (2019) Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med 25, 814-824
DOI
|
73 |
Yla-Herttuala S (2012) Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 20, 1831-1832
DOI
|
74 |
Blaese RM, Culver KW, Miller AD et al (1995) T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270, 475-480
DOI
|
75 |
Bordignon C, Notarangelo LD, Nobili N et al (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270, 470-475
DOI
|
76 |
Kohn DB, Weinberg KI, Nolta JA et al (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1, 1017-1023
DOI
|
77 |
Darrow JJ (2019) Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today 24, 949-954
DOI
|
78 |
Mahajan R (2019) Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever. Int J Appl Basic Med Res 9, 127-128
DOI
|
79 |
Lee CS, Bishop ES, Zhang R et al (2017) Adenovirusmediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis 4, 43-63
DOI
|
80 |
Basner-Tschakarjan E, Gaffal E, O'Keeffe M et al (2006) Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J Gene Med 8, 1300-1306
DOI
|
81 |
Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L and Verma I (1998) Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 95, 11377-11382
DOI
|
82 |
Hartman ZC, Kiang A, Everett RS et al (2007) Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 81, 1796-1812
DOI
|
83 |
Worgall S, Wolff G, Falck-Pedersen E and Crystal RG (1997) Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8, 37-44
DOI
|
84 |
Xiang ZQ, Yang Y, Wilson JM and Ertl HC (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219, 220-227
DOI
|
85 |
Molinier-Frenkel V, Gahery-Segard H, Mehtali M et al (2000) Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 74, 7678-7682
DOI
|
86 |
Zhong L, Granelli-Piperno A, Choi Y and Steinman RM (1999) Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. European Journal of Immunology 29, 964-972
DOI
|
87 |
Lichtenstein DL, Toth K, Doronin K, Tollefson AE and Wold WS (2004) Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 23, 75-111
DOI
|
88 |
Hilleman MR and Werner JH (1954) Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 85, 183-188
DOI
|
89 |
Crystal RG (2014) Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther 25, 3-11
DOI
|
90 |
Gaynor RB and Berk AJ (1983) Cis-acting induction of adenovirus transcription. Cell 33, 683-693
DOI
|
91 |
Graham FL, Smiley J, Russell WC and Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36, 59-74
DOI
|
92 |
Louis N, Evelegh C and Graham FL (1997) Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233, 423-429
DOI
|
93 |
Murakami P, Pungor E, Files J et al (2002) A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum Gene Ther 13, 909-920
DOI
|
94 |
Lochmuller H, Jani A, Huard J et al (1994) Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum Gene Ther 5, 1485-1491
DOI
|
95 |
Rowe WP, Huebner RJ, Gilmore LK, Parrott RH and Ward TG (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84, 570-573
DOI
|
96 |
Smith JG and Eck SL (1999) Molecular characterization of an adenoviral vector resulting from both homologous and nonhomologous recombination. Cancer Gene Ther 6, 475-481
DOI
|
97 |
Fausther-Bovendo H and Kobinger GP (2014) Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother 10, 2875-2884
DOI
|
98 |
Smith JG, Cassany A, Gerace L, Ralston R and Nemerow GR (2008) Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport. J Virol 82, 6492-6500
DOI
|
99 |
Parker AL, Waddington SN, Buckley SM et al (2009) Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol 83, 479-483
DOI
|